Early monocyte response following local ablation in hepatocellular carcinoma.
brachytherapy
flow cytometry
hepatocellular carcinoma
local ablation
monocytes
radiofrequency ablation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
06
2022
accepted:
03
10
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Local ablative therapies are established treatment modalities in the treatment of early- and intermediate-stage hepatocellular carcinoma (HCC). Systemic effects of local ablation on circulating immune cells may contribute to patients' response. Depending on their activation, myeloid cells are able to trigger HCC progression as well as to support anti-tumor immunity. Certain priming of monocytes may already occur while still in the circulation. By using flow cytometry, we analyzed peripheral blood monocyte cell populations from a prospective clinical trial cohort of 21 HCC patients following interstitial brachytherapy (IBT) or radiofrequency ablation (RFA) and investigated alterations in the composition of monocyte subpopulations and monocytic myeloid-derived suppressor cells (mMDSCs) as well as receptors involved in orchestrating monocyte function. We discovered that mMDSC levels increased following both IBT and RFA in virtually all patients. Furthermore, we identified varying alterations in the level of monocyte subpopulations following radiation compared to RFA. (A) Liquid biopsy liquid biopsy of circulating monocytes in the future may provide information on the inflammatory response towards local ablation as part of an orchestrated immune response.
Identifiants
pubmed: 36353535
doi: 10.3389/fonc.2022.959987
pmc: PMC9638411
doi:
Types de publication
Journal Article
Langues
eng
Pagination
959987Informations de copyright
Copyright © 2022 Kimm, Kästle, Stechele, Öcal, Richter, Ümütlü, Schinner, Öcal, Salvermoser, Alunni-Fabbroni, Seidensticker, Goldberg, Ricke and Wildgruber.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Immunol. 2017 May;85:222-229
pubmed: 28314211
Front Oncol. 2020 Nov 30;10:601710
pubmed: 33330100
Cancer Cell. 2016 Aug 8;30(2):308-323
pubmed: 27478039
Trends Cell Biol. 2015 Apr;25(4):198-213
pubmed: 25540894
Cancer Immunol Immunother. 2011 Mar;60(3):319-26
pubmed: 21267721
Nat Commun. 2019 Nov 28;10(1):5421
pubmed: 31780645
Cancers (Basel). 2019 Sep 06;11(9):
pubmed: 31500214
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Front Immunol. 2021 Aug 20;12:705361
pubmed: 34489957
Cell Immunol. 2021 Mar;361:104295
pubmed: 33508529
Curr Opin Immunol. 2012 Apr;24(2):233-8
pubmed: 22264927
Liver Int. 2011 May;31(5):692-9
pubmed: 21457441
Front Immunol. 2015 Aug 17;6:423
pubmed: 26347746
Cancer Immunol Immunother. 2019 Apr;68(4):687-697
pubmed: 30684003
Front Oncol. 2021 Oct 08;11:753286
pubmed: 34692537
Hepatology. 2009 Jul;50(1):261-74
pubmed: 19554540
BMC Cancer. 2019 Oct 26;19(1):1004
pubmed: 31655563
Sci Signal. 2021 Oct 12;14(704):eabb4324
pubmed: 34637328
Sci Rep. 2017 Mar 27;7(1):447
pubmed: 28348370
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Cells. 2022 Jun 20;11(12):
pubmed: 35741108
Trends Cancer. 2016 Oct 1;2(1):20-34
pubmed: 26949745
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Hepatol. 2013 Jan;58(1):58-64
pubmed: 22925812
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):25-36
pubmed: 30580568
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Diagn Interv Imaging. 2015 Jun;96(6):625-36
pubmed: 25998997
Hepatol Int. 2020 Sep;14(5):776-787
pubmed: 32740886
World J Gastrointest Pathophysiol. 2015 Aug 15;6(3):43-50
pubmed: 26301117
J Exp Med. 2015 Apr 6;212(4):447-56
pubmed: 25800956
Front Oncol. 2021 Aug 26;11:717792
pubmed: 34513694
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Biomed Res Int. 2013;2013:187204
pubmed: 23533994
Int J Med Sci. 2021 Feb 19;18(8):1824-1830
pubmed: 33746599
Angew Chem Int Ed Engl. 2021 Feb 23;60(9):4657-4665
pubmed: 33217194
Onco Targets Ther. 2019 Sep 02;12:7129-7137
pubmed: 31564897
J Cancer Res Ther. 2019;15(7):1553-1560
pubmed: 31939437
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Immunity. 2018 Mar 20;48(3):399-416
pubmed: 29562192
Dig Dis. 2022;40(4):458-467
pubmed: 34348282
J Transl Med. 2016 Jan 06;14:2
pubmed: 26733325
Mol Imaging Biol. 2021 Apr;23(2):196-207
pubmed: 32989622
Sci Rep. 2018 Feb 7;8(1):2535
pubmed: 29416061
Biomedicines. 2021 Apr 02;9(4):
pubmed: 33918295
Cancer Immunol Immunother. 2019 Dec;68(12):1959-1969
pubmed: 31641797
PLoS One. 2022 Mar 21;17(3):e0264307
pubmed: 35312680
Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):35-42
pubmed: 27765768
Nature. 2001 Jan 11;409(6817):198-201
pubmed: 11196644
Nat Commun. 2021 May 5;12(1):2526
pubmed: 33953190